Moderna’s ‘year of transition’: Changing gears from Covid-19 to RSV as vaccine approval date looms
Wrapping what it calls a “year of transition,” Moderna is further expanding its commercial operations toward the potential launch of its RSV vaccine while downsizing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.